Romanian doctors and pharmaceutical companies under anticorruption investigation Reviewed by Momizat on .   [caption id="attachment_5412" align="alignnone" width="615"] “According to the National Anticorruption Directorate (DNA), pharmaceutical companies offere   [caption id="attachment_5412" align="alignnone" width="615"] “According to the National Anticorruption Directorate (DNA), pharmaceutical companies offere Rating: 0

Romanian doctors and pharmaceutical companies under anticorruption investigation

 

“According to the National Anticorruption Directorate (DNA), pharmaceutical companies offered doctors working in hospitals in the Mures, Salaj, Sibiu, Bistrita-Nasaud and Cluj counties various rewards for prescribing the drugs they produced or distributed,” the newswire announced.

“According to the National Anticorruption Directorate (DNA), pharmaceutical companies offered doctors working in hospitals in the Mures, Salaj, Sibiu, Bistrita-Nasaud and Cluj counties various rewards for prescribing the drugs they produced or distributed,” the newswire announced.

Arrangements among Romanian doctors and pharmaceutical companies regarding prescription of cancer drugs are being investigated by anticorruption prosecutors in Romania, the Romanian newswire, the Romania Insider, reported July 29.

“According to the National Anticorruption Directorate (DNA), pharmaceutical companies offered doctors working in hospitals in the Mures, Salaj, Sibiu, Bistrita-Nasaud and Cluj counties various rewards for prescribing the drugs they produced or distributed,” the newswire announced.

Rewarded doctors were allegedly offered paid travel to international medical conventions, as well as leisure trips to other countries. According to judicial sources, the rewards for doctors are considered as a bribe. One pharmaceutical company paid almost EUR 1 mln in 2014 to a tourism operator. Some of pharmaceutical companies sponsored allegedly various trips.

“In return, the investigated doctors prescribed the drugs produced or distributed by these companies, instead of generic drugs, which are cheaper, but have similar effects,” the newswire, based on judicial sources and quoted by local media, reported. “The scheme also artificially increased the number of patients who benefited from these expensive treatments and created unjustifiably high inventories of such drugs in some public hospitals, which damaged the National Social Health Insurance Fund.”

Judicial sources informed that sixteen doctors are under investigation. Swiss pharmaceutical company, Roche is also being investigated. 

 

Photo courtesy of National Cancer Institute

Scroll to top